Articles published by Acrivon Therapeutics, Inc
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
August 13, 2024
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
May 14, 2024
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
February 27, 2024
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2024
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 21, 2023
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 09, 2023
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 28, 2023
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2023
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 11, 2023
Via GlobeNewswire
Tickers
ACRV
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
![](https://ml.globenewswire.com/media/7935747b-f8f5-48e8-b925-6935300d63e5/small/acrivon-logo-jpg.jpg)
Via GlobeNewswire
Tickers
ACRV
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.